Comparative study of cerebrospinal fluid α‐synuclein seeding aggregation assays for diagnosis of Parkinson's disease

PD diagnosis is based primarily on clinical criteria and can be inaccurate. Biological markers, such as α‐synuclein aggregation, that reflect ongoing pathogenic processes may increase diagnosis accuracy and allow disease progression monitoring. Though α‐synuclein aggregation assays have been published, reproducibility, standardization, and validation are key challenges for their development as clinical biomarkers.

[1]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[2]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[3]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[4]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[5]  B. Permanne,et al.  Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding , 2001, Nature.

[6]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[7]  Geert Mayer,et al.  The REM sleep behavior disorder screening questionnaire—A new diagnostic instrument , 2007, Movement disorders : official journal of the Movement Disorder Society.

[8]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[9]  F. Barrero,et al.  Plasma α‐synuclein in patients with Parkinson's disease with and without treatment , 2010, Movement disorders : official journal of the Movement Disorder Society.

[10]  S. Fahn.  Parkinson's disease: 10 years of progress, 1997–2007 , 2010, Movement disorders : official journal of the Movement Disorder Society.

[11]  Aneeka M Hancock,et al.  DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. , 2010, Brain : a journal of neurology.

[12]  Brent Race,et al.  Rapid End-Point Quantitation of Prion Seeding Activity with Sensitivity Comparable to Bioassays , 2010, PLoS pathogens.

[13]  W. Poewe,et al.  The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[14]  Brit Mollenhauer,et al.  α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.

[15]  Fred H. Gage,et al.  In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.

[16]  O. Levy,et al.  The neuropathology of genetic Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[17]  Danna Jennings,et al.  Impaired olfaction and other prodromal features in the Parkinson At‐Risk Syndrome study , 2012, Movement disorders : official journal of the Movement Disorder Society.

[18]  Mathias Jucker,et al.  Self-propagation of pathogenic protein aggregates in neurodegenerative diseases , 2013, Nature.

[19]  G. Halliday,et al.  DAT‐SPECT diagnoses dopamine depletion, but not PD , 2014, Movement disorders : official journal of the Movement Disorder Society.

[20]  G. Deuschl,et al.  Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[21]  J. Trojanowski,et al.  Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. , 2015, JAMA neurology.

[22]  M. Esiri,et al.  Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies , 2016, Annals of clinical and translational neurology.

[23]  Arthur W. Toga,et al.  CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study , 2016, Acta Neuropathologica.

[24]  M. Frasier,et al.  The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort , 2016, Movement disorders : official journal of the Movement Disorder Society.

[25]  P. Calabresi,et al.  Cerebrospinal fluid β‐glucocerebrosidase activity is reduced in parkinson's disease patients , 2017, Movement disorders : official journal of the Movement Disorder Society.

[26]  C. Tanner,et al.  Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[27]  P. Calabresi,et al.  Diagnostic utility of cerebrospinal fluid α‐synuclein in Parkinson's disease: A systematic review and meta‐analysis , 2017, Movement disorders : official journal of the Movement Disorder Society.

[28]  B. Mollenhauer,et al.  Development of a Biochemical Diagnosis of Parkinson Disease by Detection of &agr;-Synuclein Misfolded Aggregates in Cerebrospinal Fluid , 2017, JAMA neurology.

[29]  L. Parnetti,et al.  Are We Ready for Detecting α-Synuclein Prone to Aggregation in Patients? The Case of “Protein-Misfolding Cyclic Amplification” and “Real-Time Quaking-Induced Conversion” as Diagnostic Tools , 2018, Front. Neurol..

[30]  John L. Robinson,et al.  Cellular Milieu Imparts Distinct Pathological α-Synuclein Strains in α-Synucleinopathies , 2018, Nature.

[31]  L. Shaw,et al.  Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features , 2017, Movement disorders : official journal of the Movement Disorder Society.

[32]  D. Galasko,et al.  Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC , 2018, Acta Neuropathologica Communications.

[33]  E. Tolosa,et al.  Lack of central and peripheral nervous system synuclein pathology in R1441G LRRK2-associated Parkinson’s disease , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.